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Background: Considering the distinct biological characteristics of Plasmodium species is crucial for control and
elimination efforts, in particular when facing the spread of drug resistance. Whereas the evolutionary fitness of all
malarial species could be approximated by the probability of being taken by a mosquito and then infecting a new
host, the actual steps in the malaria life cycle leading to a successful transmission event show differences among
Plasmodium species. These “steps” are called fitness components. Differences in terms of fitness components may affect
how selection imposed by interventions, e.g. drug treatments, differentially acts on each Plasmodium species. Thus,
a successful malaria control or elimination programme should understand how differences in fitness components
among different malaria species could affect adaptive evolution (e.g. the emergence of drug resistance). In this
investigation, the interactions between some fitness components and natural selection are explored.
Methods: A population-genetic model is formulated that qualitatively explains how different fitness components
(in particular gametocytogenesis and longevity of gametocytes) affect selection acting on merozoites during the
erythrocytic cycle. By comparing Plasmodium falciparum and Plasmodium vivax, the interplay of parasitaemia and
gametocytaemia dynamics in determining fitness is modelled under circumstances that allow contrasting solely the
differences between these two parasites in terms of their fitness components.
Results: By simulating fitness components, it is shown that selection acting on merozoites (e.g., on drug resistant
mutations or malaria antigens) is more efficient in P. falciparum than in P. vivax. These results could explain, at least in
part, why resistance against drugs, such as chloroquine (CQ) is highly prevalent in P. falciparum worldwide, while CQ is
still a successful treatment for P. vivax despite its massive use. Furthermore, these analyses are used to explore the
importance of understanding the dynamic of gametocytaemia to ascertain the spreading of drug resistance.
Conclusions: The strength of natural selection on mutations that express their advantage at the merozoite stage is
different in P. vivax and P. falciparum. Species-specific differences in gametocytogenesis and longevity of gametocytes
need to be accounted for when designing effective malaria control and elimination programmes. There is a need for
reliable data on gametocytogenesis from field studies.
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Malaria burden has made this disease a significant bar-
rier for reaching global development. Malaria, however,
is not one disease. Whereas Plasmodium falciparum is
responsible for most cases in Africa, endemic regions
outside of Africa are characterized by the presence of
Plasmodium vivax, the second most important malaria
parasite in terms of its morbidity. Although they are
found in sympatry across endemic regions worldwide,
there are well-known differences between P. falciparum
and P. vivax. Indeed, they differ in key aspects of their
basic biology, geographic range, and evolutionary origins
[1-4]. Such distinctive characteristics affect control and
elimination managements of these two malarias; specif-
ically in terms of (i) treatment of their associated clinical
diseases and (ii) the design of new control tools, such as
choosing candidates for anti-malarial vaccines.
Regardless of these noticeable biological differences, it
has not been properly discussed yet how interventions
acting as selective forces (e.g. anti-malarial drugs) differ-
entially affect each species. Such assessment is important
considering that malaria elimination will face areas
where these two parasites are prevalent. Even in Africa,
where P. vivax is rightfully neglected when compared
with the impact of P. falciparum, there is increasing
evidence indicating that this parasite is present, but at a
lower prevalence [5,6].
An example of differences between these two species,
in terms of emerging adaptations hampering the efficacy
of interventions, can be found in the onset of chloro-
quine (CQ) resistance. Whereas in P. falciparum CQ
resistance originated and spread worldwide as result of
several independent events [7], it remains the drug of
choice for treating P. vivax in most areas worldwide.
CQ-resistant P. vivax strains are typically present – if at
all – at low prevalence, and resistance-levels are low
compared with P. falciparum [8]. Why did drug resist-
ance emerge slower in P. vivax? There are ad hoc expla-
nations for this observation, e.g., resistance may have a
greater cost in P. vivax or that CQ targets a different path-
way in this parasite. Although these explanations are un-
doubtedly intuitive, they might confuse other mechanisms.
Likewise, there is extensive evidence of balancing selection
acting on major malaria antigens expressed in the mero-
zoite stage in P. falciparum, whereas in P. vivax such pat-
terns are harder to detect [9-12]. Again, it could be argued
that the immune system does not necessarily recognize the
same antigens equally efficiently in both parasites. More-
over, there are some species-specific proteins involved in
the invasion of the red blood cells that could alter the over-
all immune response ([13] and references within there).
Regardless of the intellectual merit of these ad hoc expla-
nations, it is worth exploring alternative arguments based
on formal foundations; this allows proposing hypothesessusceptible to be tested with empirical data. Consequently,
operational research will be enriched by providing new
perspectives that will support sustainable evidence-based
malaria-elimination programmes. Following this logic, this
article discusses how the distinct biological characteristics
of different Plasmodium species may explain, at least in
part, the differences observed in terms of patterns asso-
ciated with some forms of positive selection.
Successful transmission of malaria is characterized by
many steps, which are referred to as fitness components.
Although, malaria fitness in terms of successful trans-
mission can be roughly summarized in the same way
across all species (e.g. number of infected mosquitoes
per sporozoite in the original infection), the relative
weights of the involved fitness components differs
among them due to species-specific characteristics. For
example, P. vivax has hypnozoites and P. falciparum
produces gametocytes relatively late and with a longer
lifespan when compared with P. vivax [1,14-16]. Thus,
interventions will likely affect the dynamic of mutations
that could confer an advantage to the parasite (e.g. drug
tolerance or resistance) differently in each species even
if those mutations potentially offer the same relative
metabolic advantage. Consequently, it could be hypothe-
sized that differences in fitness components could make
selection acting on the erythrocyte stages less efficient as
an evolutionary force in one parasite species when com-
pared with the other. This is a fundamental question in
order to ascertain the effect of selection on the dynamic
of mutations that could have a global health impact.
Whereas there are several differences in term of fitness
components between the two parasite species, by propos-
ing a population-genetic model, this investigation specific-
ally explores how differences in gametocytaemia in terms
of their time of production and lifespan may affect the
dynamics of an advantageous mutation expressed in the
merozoite stage. Real examples of such mutations are the
ones conferring drug resistance but similarities could be
made in the case of variants associated with vaccine eva-
sion or even polymorphisms maintained by balancing se-
lection. However, for simplicity, this investigation focuses
on mutations associated with resistance (or tolerance) to
drugs acting at the merozoite stage. Overall, this investiga-
tion suggests that positive selection is by far less efficient
as a driving force in P. vivax in mutations that express
their metabolic (or immunologic) advantage during the
merozoite stage. Although, this investigation concentrates
only on the two clinically most relevant human malarias,
the models and reasoning are valid for comparisons be-
tween any two human malaria species with obvious modi-
fications. The results presented here are further discussed
in terms of the importance of understanding gametocytae-
mia, not only in terms of its pivotal role in malaria trans-
mission, but also in ascertaining the effect that natural
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spreading mutations that may compromise the lifespan of
tools used for control and elimination.
Methods
Basic terminology and assumptions
For the present purposes, parasitaemia and gameto-
cytaemia are considered as population averages. In a
single malaria episode, parasitaemia increases in
discrete cycles and will be under strong stochastic
fluctuations. However, averaged over all malaria episodes
in the population, parasitaemia will approximately follow
a deterministic, continuous growth function (see Figures 1
and 2). The same holds for the gametocytaemia dynamics.
In particular, not every malaria infection has gameto-
cytaemia, but the population average will again follow
a deterministic growth function.
In what follows ‘resistant’, ‘sensitive’, and ‘drug pressure’
can be substituted (with the necessary modifications) by
‘beneficial’, ‘deleterious’, and ‘selective force’, respectively,
to obtain a more general interpretation. Resistant para-
sites might be associated with metabolic costs [17,18].
Hence, the population-average dynamics of resistant and
sensitive parasites will be different, even in the absence
of drug pressure. Notably, the emphasis of this population
genetic model is on the ensemble of the various fitness
components for each parasite species, not on the specifics
of the parasitaemia and gametocytaemia dynamics.
Overall, this population genetic model is used to
compare P. vivax and P. falciparum in terms of how
two specific fitness components, time of gametocyte
production and their lifespan, affect the dynamics of
an advantageous mutation expressed in the merozoite
stage. Thus, the figures properly summarize the
results. In order to contrast the importance that differ-
ences in gametocytaemia dynamics may have, a specific
example on the effect of patient isolation may have on
the spread of mutations associated with resistance in
P. vivax and P. falciparum is discussed. The mathem-
atical detail and the parameters chosen are described
below. Readers shall feel free to skip the mathematical
details as the figures guide the intuitive argument
without mathematical formalism.
Model
Evolutionary dynamics
Schneider and Kim [19,20] derived a model for the
spread of resistant associated mutations tailored to the
transmission cycle of P. falciparum. The model incorpo-
rated the possibility of co-infections, different numbers
of sporozoites or sporozoite-strains infecting hosts, and
heterogeneity among hosts (e.g., due to treated and
untreated infections). Denoting the relative frequency of
resistant parasites in generation t by p(t), it was shownthat the evolutionary dynamics follow the recursion
equation
p tð Þ ¼ p 0ð Þλ
t
p 0ð Þλt þ 1 p 0ð Þð Þμt ¼
1
1þ 1p 0ð Þp 0ð Þ λμ
 t ; ð1Þ
where time t is measured in discrete units of transmission
cycles (i.e., one generations corresponds to one full trans-
mission cycle - from sporozoite to sporozoite). Moreover, λ
and μ are the fitnesses of resistant and sensitive parasites
averaged over heterogeneous clusters of hosts with different
responses to the infection, e.g., over treated and untreated
hosts. The average fitnesses λ and μ are the likelihoods that,
respectively, resistant or sensitive sporozoites causing an
infection lead to gametocyte-offspring that are taken by a
mosquito during its blood meal. Therefore, fitness is the
results of various events that take place during the life
cycle, the fitness components. Particularly, λ and μ depend
on the average parasitaemia and gametocytaemia dynamics
within infections. In the following, it is explained how the
various fitness components assemble. From (1) it is clear
that only the ratio λμ (the relation between the fitnesses of
resistant and sensitive parasites) is considered in the evolu-
tionary dynamics. If a mutation occurs that renders a para-
site to be resistant – either in the human host or mosquito
vector – initially only few sporozoites in one or a few mos-
quitoes will be resistant. Hence, if N denotes the number of
sporozoites counted over all mosquitoes participating in a
given transmission cycle, the initial frequency of resistant
parasites p(0) is on the order of 1N . Notably, the formulation
of the model incorporated co-infections by several mosqui-
toes. However, the dynamics and spread of resistant-
associated mutations (at a single locus) are independent
from the likelihood of co-infections (for more details see
[19]). The situation would change with mutations interact-
ing at two linked loci; however, such a more complex
scenario is not considered at this point.
The transmission cycle for P. vivax is similar to that of
P. falciparum, an important difference is that P. vivax
infections involve liver-stage hypnozoites that can result
in relapses. In a model that considers different merozoite
variants [19,20], this can be approximated by assuming a
higher likelihood of co-infections, since relapses will
generate overlapping parasite generations. Ideally, the
fitnesses of resistant and sensitive parasites in P. vivax need
to be adjusted accordingly by considering the evolutionary
dynamics of hypnozoites. This is especially important if
hypnozoites are never treated in the population. However,
such models involve different sets of assumptions that
should be explored somewhere else.
Parasitaemia dynamics
The most obvious process determining fitness is parasit-
aemia. Population-average blood-stage parasitaemia of,
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Figure 1 Intra-host and population-level dynamics resulting from fitness components. A) Population-average dynamics of asexual
parasitaemia as a function of time after the erythrocytic cycle’s onset. They dynamics are shown separately for the resistant and sensitive parasites
following equation (2). The y-axes on the left and right side correspond to the P. falciparum and P. vivax respectively. The dynamics are identical
up to a scaling constant. On day seven drugs are administered to eliminate parasites. Resistant parasites are eliminated slightly less efficiently. B)
Population-average gametocytaemia derived from the parasitaemia dynamics in A). Whereas, gametocytes are produced readily in P. vivax, they
appear much later in P. falciparum. The dynamics are according to Equations (3) and (4). Vertical lines in A) and B) mark important events in a
clinical episode. C) Spread of a resistant mutation - according to equation (1) - in P. falciparum and P. vivax is determined by the ratio of the areas
under the curve of the gametocytaemia dynamics of resistant over sensitive parasites derived from B). Shown is the frequency of the resistant
mutation as a function of time measured in generations corresponding to transmission cycles. The horizontal lines show the fitness ratio of
resistant over sensitive parasites with corresponding right-hand side y-axis. Parameters are as described in Methods.
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absence of drugs is modelled according to the Holling
Type III functions
PS tð Þ ¼ Pmax1þξρτ and PR τð Þ ¼ Pmax1þξρτS Rwhere Pmax is the threshold parasitaemia, i.e., the max-
imum number of parasites that can be sustained within an
infection. Here, PS and PR correspond to growth para-
meters of resistant and sensitive parasites, and ξ is a fitting
parameter. The above dynamic imply exponential growth
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Figure 2 (See legend on next page.)
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of sensitive and resistant parasites at low density after a
slow initial establishment. However, once the parasitaemia
approaches Pmax, it will level off due to a carrying capacity.
The Greek letter τ refers to the time scale of the duration
of an average infection. Moreover, τ = 0 denotes the start
of blood stage parasitaemia (erythrocytic cycle), and τ is
scaled in days. The relation ρS > ρR implies metabolic costs
for resistance, i.e., a slower growth of resistant parasites
[17,18].
After, the onset of drug treatment, parasitaemia will
decrease exponentially. In particular, the dynamics are
modelled by PS τð Þ ¼ Pmax1þξρτS e
δs ττ0ð Þ and PR τð Þ ¼ Pmax1þξρτR
eδR ττ0ð Þ for τ > τ0, where τ0 denotes the time that
drugs become effective, and δS, and δR denote the death
rates of sensitive and resistant parasites, respectively.
Naturally, δS > δR holds.
Moreover, Pmax is replaced by Pmax
falc and Pmax
vivax to spe-
cifically model P. falciparum and P. vivax. Hence, apart
from a scaling constant both parasite species are
assumed to follow the same parasitaemia dynamics. In a
more compact form these are given by
P τð Þ ¼
P
1þ ξρτ
f τð Þ ð2Þ
where f τð Þ ¼ eδ∗ ττ0ð Þ for τ > τ0 and f(τ) ≡ 1 for τ >
τ0 (the asterisk in the subscript is a placeholder for R
and S, and that in the superscript for falc and vivax).
The above parasitaemia dynamics are population
averages including all treated and untreated infections.
Gametocytaemia dynamics
While parasitaemia dynamics determine the performance
of parasites within an average malaria episode, parasites’
fitnesses on a population scale are determined by their
ability to transmit to other hosts. The fitness component
determining transmissibility is summarized by the gameto-
cytes’ dynamics. The population-average gametocytaemia,
after its appearance, is assumed to be proportional to the
population-average parasitaemia.
In P. falciparum episodes gametocytes appear at a later
stage of the infection [1,14-16]. The average dynamics
among P. falciparum infections are assumed to follow
GfalcS τð Þ ¼ φPfalcS τð Þgfalc τð Þ and
GfalcR τð Þ ¼ φPfalcR τð Þ
ð3Þ
where φ is the percentage of blood-stage parasites develop-
ing into gametocytes. Moreover, gfalc(τ) = 0 for τ1
falc > τ > 0
gfalc(τ) = 64(τ− τ1
falc)3 gfalc(τ) = 0 for τ1
falc > τ > 0, gfalc(τ) = 64(τ
− τ1
falc)3(1 − τ + τ1
falc)3 for τfalc1 þ 12 > τ > τfalc1 and gfalc(τ)
= 1 for τ > τfalc1 þ 12 . The function gfalc(τ) ensures that
gametocytaemia has a smooth onset over 12 hours and
does not immediately jump from zero to φPmax
falc . This is
mainly for illustrative purposes. The outcome of the
model is independent of the particular choice of this
function.
Gametocytaemia appears readily in P. vivax infections,
i.e., at time τ1
vivax = 0 [1,14-16]. Hence, the gametocytae-
mia dynamics follow
GvivaxS τð Þ ¼ vPvivaxS τð ÞfS τð Þgvivax τð Þ and
GvivaxR τð Þ ¼ vPvivaxR τð ÞfR τð Þgvivax τð Þ
ð4Þ
where v is the percentage of blood-stage parasites devel-
oping into gametocytes in P. vivax and gvivax(τ) is
defined as gfalc(τ) with τ1
falc replaced by τ1
vivax.
Note, that the functions g (τ) account for the different
onsets of gametocytogenesis in P. falciparum and P. vivax.
Namely, gametocytogenesis starts with the erythrocytic
cycle in P. vivax, (about a week before drug treatment
starts). However, in P. falciparum gametocytogenesis
starts shortly before drug treatment starts [1,14,16].
Life-span of gametocytes
Alternatively to the above, more realistic gametocytaemia
dynamics can be assumed by including an additional fitness
component. Namely, gametocytes are non-reproducing;
they derive from merozoites and die after a while if they
are not transmitted by a mosquito vector.
Hence, the number of gametocytes at time τ in,
respectively, P. falciparum and P. vivax are
G falc τð Þ ¼
Zτ
Max 0;τβfalc½ 
φP falc zð ÞfS zð Þgfalc zð Þdz ð5Þ
and
(See figure on previous page.)
Figure 2 Intra-host dynamics with refined gametocytaemia. A) As Figure 1A with parameters described in Methods. B) As compared to
Figure 1B, gametocytes are not just assumed to be proportional to merozoites but their longevity is incorporated – according to Equations (5)
and (6) respectively. The grey shaded area indicates a period of isolation in which no transmission can occur, and is only relevant for figure D. C)
as Figure 1C but fitness is derived from Figure 2B and (7). D) As in Figure C, but the two-day isolation (indicated in grey in Figure B) according to
equation (8) is taken into account. Hence, the gametocytaemia dynamics in the grey shaded area are disregarded for the derivation of fitness.
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Zτ
Max 0;τβvivax½ 
νPvivax zð Þf zð Þgvivax zð Þdz
ð6Þ
where βvivax and βfalc are the life spans of gametocytes in
P. vivax and P. falciparum, respectively.
Fitness
The various fitness components can be combined to
determine fitness. The fitness of a parasite is the prob-
ability that a gametocyte offspring is transmitted to a
different host, and hence can further participate into
the transmission cycle. Any gametocyte can be picked
up by a mosquito whenever gametocytaemia exceeds a
threshold Gcrit
vivax, or Gcrit
falc for P. vivax or P. falciparum,
respectively. Hence, the fitnesses of parasites are pro-
portional to the respective mean value of the average
gametocytaemia, which is taken over the time window
when gametocytaemia exceeds its threshold. Hence fitness
is proportional to
Zb
a
G τð Þdτ.
Here, (aR
vivax, bR
vivax), (aS
vivax, bS
vivax), (aR
falc, bR
falc), (aS
falc, bS
falc),
denote the time intervals in which resistant and sensitive
gametocytes exceed the threshold gametocytaemia to be
transmittable in P. vivax, and P. falciparum, respectively.
This implies a density-dependence in fitness.
Thus, the fitness advantage of resistant over sensitive
parasites in P. vivax and P. falciparum are
λ
μ
¼
ZbR
aR
GR τð Þdτ
ZbS
aS
GS τð Þdτ
: ð7Þ
Note, that in Schneider and Kim [19] λ and μ are aver-
aged over treated and untreated hosts (or heterogeneous
clusters of hosts). Here this is already accounted for by
regarding the population-average parasitaemia and game-
tocytaemia dynamics.
Isolation of patients
As a standard healthcare procedure, malaria patients
might be isolated by using bed nets. During isolation, mal-
aria cannot be transmitted, which results in an additional
fitness component. Hence, this needs to be accounted for
when deriving fitnesses of resistant and sensitive parasites
on a population level. In particular, if the patient isolationis sustained For τQ days, the fitnesses are proportional to
Zb
a
G τð ÞI τ0;τ0þτQ½  τð Þdτ; and the fitness ratios become
λ
μ
¼
ZbR
aR
GR τð ÞI τ0;τ0þτQ½  τð Þdτ
ZbS
aS
GS τð ÞI τ0;τ0þτQ½  τð Þdτ
: ð8Þ
Here, I τ0;τ0þτQ½  τð Þ ¼ 1 for τ0 < τ < τ0 + τQ and 0 other-
wise. In other words, whereas gametocytaemia during
the patient isolation period is assumed irrelevant in
terms of transmission, isolation of patients changes the
relative fatnesses of resistant versus sensitive parasites.
Of note, the changes in fitness are qualitatively and
quantitatively different in P. falciparum and P. vivax,
since dynamics of gametocytaemia are different between
these species.
Parameter choice
To lay out the formal arguments, parameters are chosen
that are intuitive and lead to within-host and evolution-
ary dynamics that biologically meaningful.
First, note that the ratio of resistant and sensitive
fatnesses or λμ is independent of the choice of Pmax
vivax,
Pmax
falc , v, and φ, if Gcrit
vivax and Gcrit
falc are properly scaled.
Hence, the merit of keeping these parameters is to provide
examples with realistic values for gametocytaemia and
parasitaemia when P. falciparum and P. vivax are con-
trasted. Moreover, note that the parameters were chosen to
achieve illustrative and representative examples. Hence,
their concrete values are of secondary importance.
The following parameters determining parasitaemia
dynamics are assumed: Pmax
vivax= 104/μL, Pmax
falc = 5 * 105/μL
[21], and ξ=105 For the basic model determined by
Equations (1) – (4) the parameters ρS ¼ 1007 ; ρR ¼
100
7:25 ; δS ¼ 1:5 and δR ¼ 1:35 are used, which implies
slight metabolic cost for resistance. For the model account-
ing for gametocytes’ life-span, ρS ¼ 1007 ; ρR ¼ 1007:5 ; δS ¼
1:5 and δR ¼ 1:25 are used. These choices guarantee that
the maximum parasitaemia will be nearly reached after five
to seven days after the onset of the erythrocytic cycle. Fur-
ther, treatment is assumed to start at τ0=7.
Regarding gametocytaemia specific parameters, the
onset of gametogenesis in P. vivax is immediately after
the start of the erythrocytic cycle, i.e., τ1
vivax = 0, whereas
it is 6.5 days later in P. falciparum, i.e., τ1
falc = 6.5. The
gametocytaemia threshold for transmission is assumed
to be Gcrit
vivax =Gcrit
falc = 10/μL.
Schneider and Escalante Malaria Journal 2013, 12:15 Page 8 of 11
http://www.malariajournal.com/content/12/1/15In the basic model v = 0.05, and φ = 0.0004 were used.
In the model accounting for gametocytes’ life-span v = 0.01,
and φ = 0.0004 were used. Moreover, longevity of gameto-
cytes is set to 8 days for P. falciparum (βfalc = 8, [22]) and
2 days for P. vivax (βvivax = 2; [23]).
When isolation of treated patients is incorporated, 2 days
of isolation are assumed, i.e., τQ = 2 in equation (8).
Results
Dynamics for the simple model
The argument that is laid out here assumes quantita-
tively identical parasitaemia dynamics for P. falciparum
and P. vivax episodes. Even further, the dynamics are
identical up to a scaling constant to ensure meaningful
merozoite counts for both species. The merit of this ap-
proach is to keep some fitness components constant
allowing contrasting the impact of the remaining com-
ponents. Figure 1A shows the population-average para-
sitaemia dynamics of resistant and sensitive parasites in
P. falciparum and P. vivax. Note, that resistant parasites
are just slightly less efficiently removed than sensitive
parasites. (In fact such differences might not even mani-
fest in clinical outcomes).
Gametocytes are produced at earlier stages in P. vivax
infections when exposure to antimalarial drugs is un-
likely. Hence, during an infection, the time window in
which sensitive parasites are selectively advantageous
and produce gametocytes at the same time is prolonged
in P. vivax. This is depicted in Figure 1B. Therefore, over
the course of the infections, disproportionally more sensi-
tive gametocytes contribute to P. vivax transmission when
compared to P. falciparum. Consequently, this translates
into smaller fitness differences between resistant and sen-
sitive parasites in P. vivax, since fitness is determined as
the overall prevalence of gametocytes during the popula-
tion average course of infections. The dynamics for the
spread of resistance prevalence is depicted in Figure 1C.
While under these circumstances resistance spreads
within 200 generations in P. falciparum it takes 3,000
generations in P. vivax. This corresponds to 20–40 years
in P. falciparum and 300–600 years for P. vivax, assuming
5 to 10 malaria generations per year. This notorious differ-
ence is observed by simply considering that gametocytes
in P. vivax are produced earlier than in P. falciparum
during the course of an infection.
Incorporation the life span of gametocytes
The argument as laid out above, still applies if the di-
fferences in the life-span of gametocytes is incorporated
(Equations 5 and 6), as shown in Figure 2. From similar
parasitaemia dynamics (Figure 2A), the gametocytaemia
dynamics are derived (Figure 2B). Again, the prevalence of
resistant compared with sensitive gametocytes is higher in
P. falciparum episodes, resulting in stronger selection fordrug-resistance, and faster spread of resistance prevalence
in P. falciparum than in P. vivax (cf. Figure 2C).
Isolation of patients
Surprisingly, the strength of selection for drug resistance
and hence its spread, will increase by short isolation
measures (Equations 7 and 8) in clinical episodes of
P. falciparum, whereas it can be an effective mechanism
to prevent the spread of drug-resistance in P. vivax.
Figure 2D shows the spread of resistance derived from the
gametocytaemia dynamics for Figure 2B when two-day
isolation is assumed in clinical cases (see Methods).
Hence, the fitnesses are calculated as for Figure 2C, except
that the dynamics two days after the start of treatment do
not contribute to determine fitness - grey shaded area in
Figure 2B. Isolation prevents the spread of drug resistance
in P. vivax, since gametocytes have a short lifespan and
they will likely die after the onset of drug-treatment.
In P. falciparum episodes the situation differs because
gametocytes are longer lasting. Hence, during isolation,
proportionally the transmission of sensitive gametocytes
is more severely reduced than that of resistant gameto-
cytes. Shortly after the onset of drug treatment, more
sensitive than resistant gametocytes could be transmit-
ted, which however, is precluded precisely by the isola-
tion. By comparing Figure 2C with Figure 2D it becomes
clear that the spread of drug resistance is facilitated by
short-term isolation measures. Namely, it spreads within
100 generations instead of 200 generations, correspond-
ing to 10–20 years compared with 20–40 years when as-
suming 5–10 generations (transmissions cycles) per year.
Notably, these results are very sensitive on the duration
of isolation. In principle, as in P. vivax, resistance evolu-
tion can be prevented in P. falciparum if the isolation
period exceeds the longevity of gametocytes, i.e., if isola-
tion would be sustained for several weeks. However,
such possibility has no basis in reality.
Discussion
The impact of interacting parasitaemia and gametocytae-
mia dynamics on drug-resistance evolution was formally
studied. Namely, the contribution of various fitness
components to the overall fitness of sensitive and resist-
ant parasites was explored. Their basic components are,
(i) growth and decay rates under drug pressure on mero-
zoites, (ii) the starting point of gametocytogenesis, (iii)
the duration of gametocytes in the blood stream, (iv)
threshold gametocytaemia for transmissibility, and, even-
tually, (v) isolation periods of clinical malaria episodes.
The fitnesses of resistant and sensitive dynamics are ul-
timately calculated from the area under the curve of the
gametocytaemia dynamics over the time window during
which gametocytes can be transmitted. A similar reason-
ing to measure fitness was introduced earlier [24].
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gametocytaemia dynamics made here are by no means
crucial, since they affect the results only quantitatively
but not qualitatively. Indeed, in the illustrative examples
presented here, reasonable values for the parameters
were used from the literature, which might not exactly
agree with every other study. However, for the argu-
ments laid out here, only the qualitative picture that
gametocytes occur earlier in P. vivax but persist longer
in P. falciparum matters. Indeed this was confirmed in
many studies (despite ambiguous values among studies)
[1,14-16]. Overall, what matters is that late gametocyto-
genesis during the infection and longer lifespan of game-
tocytes will promote the spread of drug resistance. Thus,
when contrasting these two malarial parasites, resistance
will spread easier in P. falciparum than in P. vivax. It
shall be pointed out that the role of hypnozoites was
roughly approximated in terms of a higher prevalence of
co-infections in P. vivax than in P. falciparum. The role
of hypnozoites, especially if they are not properly trea-
ted, should be explored elsewhere.
For simplicity, the methods and results were tailored to-
wards resistance against drugs that target solely the mero-
zoite stage; however, an almost identical reasoning implies
that any traces of selection occurring acting on blood
stage merozoites will be more visible for P. falciparum
(gametocytogenesis; longevity of gametocytes).
Based on the results presented here, the use of drugs
that can clear gametocytes, e.g., primaquine (PQ), could
prevent the spread of drug-resistant solely on the basis
of its effect on critical fitness components. Whereas one
could make a solid argument about its benefits based on
its blocking transmission effect, the proposed decompos-
ition of fitness into basic components allows for under-
standing the potential benefits of using this drug in
terms of how selection acts on mutations associated
with resistance at the population level. By clearing game-
tocytes from parasites with mutations that confer resist-
ance against the primary drug, their likelihood of
transmitting will be reduced reducing their fitness ad-
vantage compared to sensitive parasites. Hence, PQ use
can potentially impede or delay the onset and spread of
resistant mutations by having an effect on the evolution-
ary dynamics of such mutations.
Transmission is the ultimate measure of the parasites’
fitness so, at this level, epidemiologic and evolutionary
arguments are expected to converge to the same con-
clusions as shown in this investigation. However, the
results here highlight the importance of gametocyte dy-
namics with a different perspective. Investigating gam-
etocyte dynamics is not only important in the usual
context of understanding and blocking transmission in an
epidemiologic sense, but it is also critical in the context of
sustaining successful malaria control strategies. Indeed,gametocyte dynamics determines how those control tools
(e.g. antimalarial drugs) act as selective forces on the para-
site population compromising their long-term efficacy.
Namely, they affect the spread of mutations that are
selected by interventions, in this case, drug resistance.
Therefore, more detailed studies on the gametocytaemia
dynamics are needed. Unfortunately, most studies reported
only on the prevalence of gametocytes in clinical episodes
on certain census points after the beginning of treatment.
However, a description of population-average gametocytae-
mia as employed here would be highly desirable. Since
such studies do not exist, we were unable to tailor our
model towards more realism. Furthermore, existing studies
[15] are often based on data from neurosyphilis patients,
and hence may not be representative for an average en-
demic area. However, as argued above, the qualitative pic-
ture will remain unchanged as it is independent of the
particular choice of gametocytaemia parameters.
Whereas this model focused on comparing two para-
sites with clear differences in their gametocytaemia dy-
namics, its findings regarding the interplay between the
efficacy of selection acting on mutations associated with
drug resistance and gametocytaemia should be consid-
ered in a broader context. E.g. it is important to consider
that the prevalence and density of gametocytaemia are
affected by particular drug treatments. For instance,
Robert et al. [25] showed that gametocytaemia preva-
lence and density is substantially higher in SP treated
patients than in CQ treated patients. Possibly, SP even
triggers gametocytogenesis or CQ prevents gametocyto-
genesis. On the other hand, artesunate seems to reduce
gametocytaemia prevalence substantially in the course of
ACT [26-30]. On the contrary, it seems that amodia-
quine (AQ) - administered as AQ or AQ+SP - leads to
high gametocytaemia prevalence compared with other
treatments [26,31-34]. Thus, it seems that there is evi-
dence indicating that some combination drug therapies
could be prone to spread resistant mutations by affecting
gametocytaemia under circumstances that need to be
properly explored. Detailed studies on the population
average gametocytaemia under different drug treat-
ments, and whenever sensitive and resistant/tolerant
parasites are present, would provide desirable informa-
tion to refine our understanding of resistance evolution.
Conclusions
By contrasting P. vivax and P. falciparum, this investiga-
tion illustrates how differences in fitness components,
time of gametocyte production and their lifespan, have a
critical effect on the efficacy of selection acting on muta-
tions that express their phenotypic effect at the mero-
zoite stage in these two parasite species. Overall,
selection at the merozoite stage is more effective in P.
falciparum than in P. vivax. These findings could
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terms of the spreading of drug resistance between these
two major malarial parasites.
The proposed model allowed exploring the differential
effect of isolating patients on these two species in terms
of the spread of mutations associated with drug resist-
ance. Even further, if transmission can be affected by
other suitable measures (other than isolation), then the
rise in frequency of advantageous mutations associated
with drug resistance at the merozoite stage will be
delayed or reduced drastically depending on the relative
role of the different fitness components. Like in previous
epidemiologic or population-biology models, this ap-
proach suggests that by employing drugs that success-
fully reduce gametocytes, the onset of drug resistance
could be delayed (e.g. using primaquine to contain the
spread of mutations associated with drug resistance or
tolerance in P. falciparum). Noteworthy, this argument
is more refined than the usual transmission-blocking
argument, namely it consists of two parts: (i) by clearing
parasites while they are advantageous against the pri-
mary drug, the fitness of resistant mutations is effect-
ively reduced; (ii) reduced gametocytaemia reduces the
likelihood of transmitting malaria, hampering the onset
and spread of resistance.
Whereas this investigation focused in compared very dif-
ferent gametocyte dynamics (P. vivax against P. falciparum),
it emphasizes the importance of gametocytaemia in terms
of the strength of selection acting on the parasite. Overall,
there is a need of monitoring gametocytaemia more care-
fully over long periods at a population level (note that
gametocytes might be carried up to 55 days [25]). More-
over, more studies on the mechanisms that may trigger
gametocytogenesis (e.g. specific drug combinations) and
the importance of submicroscopic gametocytaemia seem
highly desirable.
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